Every 8-K that Electromed, Inc. (ELMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ELMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELMD filings page.
Electromed, Inc. (ELMD) reported record results for the fourth quarter and fiscal year ended June 30, 2026, and announced a planned CEO transition. Fiscal 2026 net revenues increased 15.3% to $73.8 million, led by direct homecare revenue up 16.3% to $66.6 million. Gross profit rose to $57.9 million with a gross margin of 78.5%. Operating income grew to $13.9 million, or 18.8% of net revenues, compared to 15.1% in fiscal 2025. Net income was $11.3 million, or $1.30 per diluted share, up from $7.5 million or $0.85.
For Q4 2026, net revenues increased 11.6% to $19.4 million, with net income of $3.4 million and diluted EPS of $0.39. The company highlighted its 15th consecutive quarter of year-over-year revenue and profit growth and homecare revenue per sales representative of $1,145,000, above its $1,000,000–$1,100,000 target range. As of June 30, 2026, Electromed had $20.5 million in cash, no debt, working capital of $45.1 million, and shareholders’ equity of $54.0 million.
Electromed also disclosed that President and CEO Jim Cunniff notified the company of his intention to retire on or about April 2, 2027, and is expected to resign from the Board at that time. The Board has engaged an executive search firm and begun a comprehensive search for the next CEO.
Electromed, Inc. reported record results for its fiscal Q3 ended March 31, 2026, with net revenues of $18.6 million, up 18.4% from $15.7 million a year earlier. Growth was driven mainly by its direct homecare business, where revenue rose 18.6% to $16.7 million on more sales reps, higher productivity, and greater revenue per representative.
Gross profit increased to $14.6 million, with gross margin improving to 78.8%. Operating income jumped 76.0% to $3.8 million, lifting operating margin to 20.3%. Net income grew 58.8% to $3.0 million, or $0.35 per diluted share, compared with $0.21.
The company ended the quarter with $17.0 million in cash, no debt, working capital of $40.0 million and shareholders’ equity of $49.2 million. Over the nine-month period, Electromed generated $6.7 million in operating cash flow while repurchasing $3.9 million of its common stock.
Electromed, Inc. reported record fiscal 2026 second-quarter results, with net revenues of $18.9 million, up 16.3% from $16.3 million a year earlier. Direct homecare revenue rose 18.4% to $17.3 million, driven by more sales representatives and higher revenue per rep, which annualized at $1.2 million, above the company’s $1.0–$1.1 million target range.
Gross profit increased to $14.8 million and gross margin edged up to 78.4%. Operating income grew 42.4% to $3.6 million, lifting the operating margin to 19.2%. Net income rose 40.3% to $2.8 million, or $0.32 per diluted share, marking the 13th consecutive quarter of year-over-year revenue and net income growth.
As of December 31, 2025, Electromed held $13.8 million in cash, $36.2 million in working capital, and no debt, with shareholders’ equity of $45.4 million. Cash declined by $1.5 million over six months, mainly due to $3.8 million of share repurchases, partly offset by $3.2 million of positive operating cash flow.
Electromed, Inc. entered into a new Credit Agreement with BMO Bank N.A., providing a senior secured revolving credit facility of $10,000,000. The facility matures on December 16, 2026, and any borrowings will bear interest at one-month Term SOFR plus 1.75%, payable monthly.
The company granted a first-priority security interest in substantially all existing and future assets and agreed to customary covenants, indemnities, and events of default. While amounts are outstanding, Electromed must maintain a minimum Fixed Charge Coverage Ratio of at least 1.20x and a Total Funded Debt to EBITDA ratio of not more than 2.50x, calculated quarterly on a rolling four-quarter basis. Proceeds may be used for capital expenditures, working capital, and general corporate purposes, and the prior credit facility with Choice Financial Group was terminated.
Electromed, Inc. (ELMD) reported the results of its annual shareholder meeting held on November 14, 2025. Shareholders elected all nominated directors to the Board, with each nominee receiving substantially more votes "for" than "withheld." Other management proposals also received strong support, including the advisory vote approving executive compensation. Shareholders additionally voted on how often they want an advisory vote on executive pay, and the Board determined, based on these results, to continue including this vote in the proxy materials on an annual basis. These outcomes keep the company’s governance structure and executive pay practices largely unchanged.
Electromed, Inc. (ELMD) furnished an 8-K announcing it issued a press release with financial results for the first quarter ended September 30, 2025, and updated its investor presentation. The press release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2.
The company noted that the information, including Exhibits 99.1 and 99.2, is being furnished and not filed under the Exchange Act, and will not be incorporated by reference into a Securities Act registration statement except as specifically referenced.
Electromed, Inc. announced that its board of directors has approved a new share repurchase authorization. The company may buy back up to $10.0 million of its outstanding common stock over time through open market purchases and privately negotiated transactions. The actual amount and timing of any repurchases will depend on market conditions and other corporate considerations. Details were provided in a press release attached as an exhibit.
Electromed, Inc. disclosed that it has issued a press release reporting its financial results for the fourth quarter and fiscal year ended June 30, 2025, and furnished that press release as Exhibit 99.1 to this Form 8-K. The company also updated its investor presentation and furnished it as Exhibit 99.2, noting that the presentation may be used in meetings with investors and analysts.
The filing provides notice that the company has made results and updated presentation materials available to the market, but it does not include the financial metrics or narrative from the press release within the filing itself; interested parties must refer to the referenced exhibits for the detailed results and figures.